Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (March 2024)
22 slides from Novo Nordisk A/s Class B's investor day presentation, Mar 7, 2024
Slide 1: Research and early development
Novo Nordisk® Research and early development Marcus Schindler CSO and EVP of Research & Early development 7 MARCH JOANNA LOUISE SHARMAN-SOARES ROBERT KITCHEN Digital Science and Innovation Research Centre Oxford UK
Slide 2: Forward-looking statements
2 Research & early development Innovation and therapeutic focus Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2023 and Form 20-F, which both were filed with the SEC in
Slide 3: Strategic aspirations 2025
3 Research & early development Innovation and therapeutic focus Novo Nordisk® Strategic aspirations 2025 • Further raise the innovation-bar for diabetes treatment therapeutic focus • Progress towards zero environmental impact • Develop a leading portfolio of superior treatment Innovation and • Being
Slide 4: Innovation starts with addressing unmet needs, improving outcomes and reaching more patients
4 Research & early development Innovation and therapeutic focus Novo Nordisk® Innovation starts with addressing unmet needs, improving outcomes and reaching more patients Diabetes care Obesity care 537 million people with ~15% 813 million people with ~2% of people in of people medically diabetes1 go
Slide 5: Research and early development focuses on continuing and expanding leadership in diabetes and obesity
5 Research & early development Innovation and therapeutic focus Novo Nordisk® Research and early development focuses on continuing and expanding leadership in diabetes and obesity Therapy area priorities Strategic research focus Driving leadership in diabetes and obesity with novel and 1 Diabetes Ob
Slide 6: Increased access to human data together with AI-driven analyses enables discovery of new targets
6 Research & early development Innovation and therapeutic focus Novo Nordisk® Increased access to human data together with AI-driven analyses enables discovery of new targets Human data input Target discovery engine Increasing probability for clinical success De-risk translation from Genetics, sampl
Slide 7: SELECT trial provides a unique opportunity to identify new targets and biomarkers for future projects
7 Research & early development Innovation and therapeutic focus Novo Nordisk® SELECT trial provides a unique opportunity to identify new targets and biomarkers for future projects SELECT trial data set Fuels future research Potential outcomes Samples from • New drug targets and molecular Human data
Slide 8: Accelerating innovation through partnerships and acquisitions to grow and advance pipeline
8 Research & early development Innovation and therapeutic focus Novo Nordisk® Accelerating innovation through partnerships and acquisitions to grow and advance pipeline Number of partnerships1 and acquired assets to date Selected key highlights of partnerships and acquisitions 60+ Heart failure acti
Slide 9: CB1R inverse agonism holds potential as a novel mechanism of action
9 Research & early development Innovation and therapeutic focus Novo Nordisk® CB1R inverse agonism holds potential as a novel mechanism of action both as monotherapy and add-on treatment CB1R are found throughout the body Inversago next-generation CB1R molecules INV-347 shows weight loss in DIO mice
Slide 10: Integrating siRNA technology into Novo Nordisk adds capabilities to access intracellular targets
10 Research & early development Innovation and therapeutic focus Novo Nordisk® Integrating siRNA technology into Novo Nordisk adds capabilities to access intracellular targets across therapy areas Integration of Dicerna siRNA platform is deployed across all therapy areas GalXCTM GalXC-PlusTM Dicerna
Slide 11: siRNA platform expected to deliver and mature across therapy areas
11 Research & early development Innovation and therapeutic focus Novo Nordisk® siRNA platform expected to deliver and mature across therapy areas in alignment with corporate strategy Progress with the siRNA platform Distribution of siRNA portfolio projects Phase 1 initiation ambition with siRNA 3 11
Slide 12: Core capabilities together with additional drug modalities open up new opportunities
12 Research & early development Innovation and therapeutic focus Novo Nordisk® Core capabilities together with additional drug modalities open up new opportunities across therapy areas Core Novo Nordisk capabilities Modalities accelerated via partnerships & acquisitions Proteins/ Cell Small Gene siR
Slide 13: Novo Nordisk's modality portfolio has expanded since 2018
13 Research & early development Innovation and therapeutic focus Novo Nordisk® Novo Nordisk's modality portfolio has expanded since 2018 with more projects using newer platforms Distribution of research and phase 1 projects across modalities Strategic changes made since 2018 Build upon core capabili
Slide 14: The research and early development pipeline is broad and has increased across therapy areas
14 Research & early development Innovation and therapeutic focus Novo Nordisk® The research and early development pipeline is broad and has increased across therapy areas since 2018 Growing research and phase 1 pipeline since 2018 Strategic changes made since 2018 ~80% Continued key focus on diabete
Slide 15: Next-generation innovation drives the phase 1 pipeline within diabetes
15 Research & early development Innovation and therapeutic focus Novo Nordisk® Next-generation innovation drives the phase 1 pipeline within diabetes Diabetes phase 1 pipeline Once monthly GIP/GLP-1 co-agonist NN1845 – GSI Co-agonist to GIP Mode of action and GLP-1 receptors NN1471 – Pumpsulin Impro
Slide 16: Oral amycretin is a novel, unimolecular co-agonist of GLP-1 and amylin receptors
16 Research & early development Innovation and therapeutic focus Novo Nordisk® Oral amycretin is a novel, unimolecular co-agonist of both GLP-1 and amylin receptors that successfully completed phase 1 trial Obesity phase 1 pipeline Amycretin combines several beneficial effects of GLP-1 and amylin NN
Slide 17: Amylin shows potential for additional and complementary benefits to GLP-1
17 Research & early development Innovation and therapeutic focus Novo Nordisk® Amylin shows potential for additional and complementary benefits to GLP-1 in metabolic diseases Amylin and GLP-1 are endocrine peptide Weight loss in a 20-week phase 1 Cagrilintide improves body composition in hormones ob
Slide 18: Phase 1 results in obesity allow further clinical development of amycretin
18 Research & early development Innovation and therapeutic focus Novo Nordisk® Phase 1 results in obesity allows further clinical development of amycretin Oral amycretin phase 1 trial in obesity was successfully completed Results from exploratory endpoint on body weight change Mean baseline body wei
Slide 19: Drug development in diabetes and obesity is built around core Novo Nordisk capabilities
19 Research & early development Innovation and therapeutic focus Novo Nordisk® Drug development in diabetes and obesity is built around core Novo Nordisk capabilities Core Novo Nordisk capabilities Innovation through different approaches Building a broad Deep biology understanding pipeline Maximise
Slide 20: New standalone and tri-agonist molecule to enter phase 1 within the next 12 months
20 Research & early development Innovation and therapeutic focus Novo Nordisk® New standalone and tri-agonist molecule to enter phase 1 within the next 12 months, with new concepts to follow Expected phase 1 initiations within the next 12 months Focus areas for upcoming projects New amylin New tri-a
Slide 21: Phase 1 aspiration of bringing more targets from research to development faster is on track for 2025
21 Research & early development Innovation and therapeutic focus Novo Nordisk® Phase 1 aspiration of bringing more targets from research to development faster is on track for 2025 Key drivers increasing number of Number of phase 1 initiations in 2020 and aspirations towards 2025 phase 1 initiations
Slide 22: Closing remarks
Novo Nordisk® Closing remarks Continue to build on core capabilities and expand beyond with new modalities Pipeline is expanding, driven by internal target discovery and supported by external partnerships Phase 1 initiation ambition of 3x is on track JOANNA LOUISE SHARMAN-SOARES ROBERT KITCHEN Digit